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Abstract
Objective: To examine the use of nicotine replacement therapy (NRT) 
and the stop-smoking medicines (SSMs) varenicline and bupropion in a 
national sample of Aboriginal and Torres Strait Islander smokers and recent 
ex-smokers.
Design, settings and participants: The Talking About The Smokes (TATS) 
project used a quota sampling design to recruit a nationally representative 
sample of 1721 smokers and ex-smokers who had quit  12 months before 
from communities served by 34 Aboriginal community-controlled health 
services and one community in the Torres Strait. Baseline surveys were 
conducted from April 2012 to October 2013. These were compared with 
1017 daily smokers from the general Australian population surveyed by the 
International Tobacco Control Policy Evaluation Project (ITC Project) from 
July 2010 to May 2011.
Main outcome measures: Past and intended use of NRT and SSMs, 
duration of use, and whether participants thought NRT and SSMs help 
smokers to quit.
Results: Compared with other daily Australian smokers, lower proportions 
of Aboriginal and Torres Strait Islander daily smokers had ever used any 
NRT or SSMs (TATS, 37% v ITC, 58.5%) or used them in the past year 
(TATS, 23% v ITC, 42.1%). Nicotine patches were most commonly used 
by Aboriginal and Torres Strait Islander smokers and recent ex-smokers 
(24%), followed by varenicline (11%) and nicotine gum (10%); most (74%) 
had got their last NRT at no cost. Among dependent Aboriginal and Torres 
Strait Islander daily smokers, those who were more socioeconomically 
advantaged were more likely than the disadvantaged to have used NRT 
or SSMs. Similar proportions of Aboriginal and Torres Strait Islander daily 
smokers and other Australian daily smokers said that NRT or SSMs help 
smokers to quit (TATS, 70% v ITC, 74.2%). Dependent Aboriginal and Torres 
Strait Islander smokers who had previously used NRT or SSMs were more 
likely to believe they help in quitting and to intend to use them in the future.
Conclusion: Aboriginal and Torres Strait Islander daily smokers, particularly 
those who are most disadvantaged, are less likely to have used NRT or 
SSMs than other Australian daily smokers. Some of the barriers to use, 
including cost, are being overcome, but further improvements are possible.
Use of nicotine replacement therapy and stop-
smoking medicines in a national sample of 
Aboriginal and Torres Strait Islander smokers and 
ex-smokers
 In 2012–2013, 44% of Aboriginal and Torres Strait Islander adults smoked, 2.5 times the age-standardised prev-
alence among other Australian adults, 
and 26% were ex-smokers.1 Although 
the proportion of those who had ever 
smoked and had successfully quit was 
only 37%, compared with 63% of other 
Australians, this had increased from 
24% in 2002.1,2 Several types of nico-
tine replacement therapy (NRT; gum, 
patches, lozenges, sublingual tablets 
and inhalers) and two prescription-
only stop-smoking medicines (SSMs; 
bupropion and varenicline) are avail-
able in Australia to assist cessation.3 
All have been shown to increase the 
chance of successfully quitting, with 
varenicline and combinations of NRT 
being the most effective.4
Nicotine gum became available in 
Australia in the 1980s, followed by 
patches in the 1990s and other forms 
of NRT in the past decade.3 Over-the-
counter availability of NRT occurred 
first in pharmacies, then supermarkets. 
Subsidised availability by prescription 
for patches followed listing with the 
Pharmaceutical Benefits Scheme (PBS) 
for veterans from 1994, Aboriginal and 
Torres Strait Islander people from 2009, 
and all others from 2011. Bupropion 
was listed on the PBS in 2001, and 
varenicline in 2008.3 Since 1999, 
Aboriginal health services in remote 
areas have been able to dispense these 
PBS items at no cost through Section 
100 of the National Health Act 1953.5 In 
addition, since July 2010, many non-
remote Aboriginal health services and 
general practices participating in the 
Indigenous Health Incentive of the 
Practice Incentives Program have been 
able to reduce or eliminate the copay-
ment for all PBS medicines, including 
SSMs, for their Aboriginal and Torres 
Strait Islander patients.6
Clinical guidelines suggest that NRT, 
bupropion or varenicline be recom-
mended to all dependent smokers who 
are interested in quitting.7-9 Here, 
we explore the use of these medi-
cines and beliefs about them among 
a national sample of Aboriginal and 
Torres Strait Islander smokers and ex-
smokers. We also explore variation in 
their use among dependent smokers 
in this population, and make com-
parisons with smokers in the general 
Australian population.
Methods
The Talking About The Smokes 
(TATS) project surveyed 1643 
Aboriginal and Torres Strait Islander 
smokers and 78 recent ex-smokers 
(who had quit  12 months before), 
using a quota sampling design based 
on the communities served by 34 
Aboriginal community-controlled 
health services (ACCHSs) and one 
community in the Torres Strait. It 
has been described in detail else-
where.10,11 Briefly, the 35 sites were se-
lected based on the distribution of the 
Aboriginal and Torres Strait Islander 
population by state or territory and 
remoteness. In 30 sites, we aimed 
to interview 50 smokers or recent 
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ex-smokers and 25 non-smokers, 
with equal numbers of women and 
men, and those aged 18–34 and  35 
years. In four large city sites and the 
Torres Strait community, the sample 
sizes were doubled. People were ex-
cluded if they were aged under 18 
years, not usual residents of the area, 
staff of the ACCHS or deemed unable 
to complete the survey. In each site, 
different locally determined methods 
were used to collect a representative, 
although not random, sample. 
Baseline data were collected from 
April 2012 to October 2013. Interviews 
were conducted face to face by trained 
interviewers, almost all of whom were 
members of the local Aboriginal and 
Torres Strait Islander community. The 
survey was completed on a computer 
tablet and took 30–60 minutes. A sin-
gle survey of health service activities 
was also completed at each site. The 
baseline sample closely matched the 
distribution of age, sex, jurisdiction, 
remoteness, quit attempts in the past 
year and number of daily cigarettes 
smoked reported in the 2008 National 
Aboriginal and Torres Strait Islander 
Social Survey (NATSISS). However, 
there were inconsistent differences 
in some socioeconomic indicators: 
our sample had higher proportions of 
unemployed people, but also higher 
proportions who had completed Year 
12 and who lived in more advantaged 
areas.10
The TATS project is part of the 
International Tobacco Control Policy 
Evaluation Project (ITC Project) col-
laboration. Interview questions were 
closely based on those in ITC Project 
surveys, especially the Australian 
surveys.12 We asked all smokers and 
recent ex-smokers whether they had 
ever used NRT or SSMs, and which 
they had used. For those who had 
used NRT, we asked if they were 
currently using it, when and for how 
long they last used it, where they got 
it and if it was free, and whether they 
would use it again in the future. We 
asked similar questions of those who 
had used SSMs. We asked all smokers 
and recent ex-smokers whether they 
thought NRT and SSMs help smokers 
to quit, and about their quit attempts 
and sociodemographic factors. The 
questions are described in detail in 
Appendix 1.
We used the Heaviness of Smoking 
Index (HSI) to assess dependence 
among daily smokers. The HSI 
was coded 0 to 6 based on the sum 
of the responses to two questions: 
cigarettes per day (CPD) and time 
to first cigarette (TTFC). These 
items were each coded as 0 (0–10 
CPD; TTFC,  61 min), 1 (11–20 CPD; 
TTFC, 31–60 min), 2 (21–30 CPD; 
TTFC, 6–30 min) or 3 ( 31 CPD; 
TTFC,  5 min).13 We categorised 
HSI as low (0–1), moderate (2–3) or 
high (4–6).14,15 We also assessed the 
three criteria for dependence in the 
Royal Australian College of General 
Practitioners (RACGP) cessation 
guidelines: TTFC  30 min, > 10 CPD, 
and withdrawal symptoms on pre-
vious quit attempts (defined in our 
sample as strong cravings during the 
most recent quit attempt).7 
TATS project results were compared 
with those of 1017 daily smokers sur-
veyed in Wave 8 of the Australian 
ITC Project between July 2010 and 
May 2011. The ITC Project survey 
was completed by random digit tele-
phone dialling or on the internet, 
and included smokers contacted for 
the first time and those who were 
recontacted after completing surveys 
in previous waves. For respondents 
who had completed surveys in pre-
vious waves, the ITC Project ques-
tions about use of NRT or SSMs were 
different to the TATS project ques-
tions, so for these comparisons we 
included only the 189 daily smokers 
who were newly recruited to the ITC 
Project.
The project was approved by 
three Aboriginal human research 
1  Aboriginal and Torres Strait Islander use of nicotine replacement therapy (NRT) or stop-smoking medicines (SSMs)
Ever used NRT or SSMs Used NRT or SSMs in the past year
Smoking characteristic % (frequency)* Odds ratio (95% CI)† P‡ % (frequency)* Odds ratio (95% CI)† P‡
Smokers and recent ex-smokers (n = 1721)
Smoking status
Daily smokers 37% (515) 1.0 < 0.001 23% (318) 1.0 0.001
Non-daily smokers 17% (43) 0.35 (0.24–0.51) 12% (30) 0.46 (0.29–0.73)
Recent ex-smokers§ 36% (28) 0.94 (0.57–1.55)  32% (25) 1.59 (0.95–2.66)
Daily smokers only (n = 1369)
Heaviness of Smoking Index score
Low (0–1) 30% (69) 1.0 < 0.001 18% (42) 1.0 0.06
Moderate (2–3) 36% (284) 1.34 (1.00–1.81) 23% (184) 1.39 (0.92–2.08)
Heavy (4–6) 45% (148) 1.98 (1.42–2.76) 27% (86) 1.65 (1.08–2.51)
RACGP criteria for dependence¶
None 24% (38) 1.0 < 0.001 13% (20) 1.0 < 0.001
One 27% (91) 1.23 (0.78–1.92) 17% (55) 1.38 (0.84–2.28)
Two 35% (192) 1.71 (1.12–2.61) 21% (118) 1.89 (1.11–3.22)
All three 59% (193) 4.66 (2.99–7.27) 39% (125) 4.39 (2.56–7.51)
RACGP = Royal Australian College of General Practitioners. * Percentages and frequencies exclude those answering “don’t know” or refusing to answer. † Odds ratios calculated 
using simple logistic regression adjusted for the sampling design. ‡ P values for the entire variable, using adjusted Wald tests. § Those who had quit  12 months before. ¶ Time to 
first cigarette  30 min, > 10 cigarettes per day, and withdrawal symptoms on previous quit attempts (strong cravings during most recent quit attempt). 
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ethics committees (HRECs) and 
two HRECs with Aboriginal sub-
committees: Aboriginal Health & 
Medical Research Council Ethics 
Committee, Sydney; Aboriginal 
Health Research Ethics Committee, 
Adelaide; Central Australian HREC, 
Alice Springs; HREC for the Northern 
Territory Department of Health and 
Menzies School of Health Research, 
Darwin; and the Western Australian 
Aboriginal Health Ethics Committee, 
Perth.
Statistical analyses
We calculated the percentages and 
frequencies of responses to the TATS 
project questions, but did not include 
confidence intervals for these as it 
is not considered statistically ac-
ceptable to estimate sampling error 
in non-probabilistic samples. We 
compared results for daily smokers 
with those from the Australian ITC 
Project, which were directly stand-
ardised to the distribution of age and 
sex of Aboriginal and Torres Strait 
Islander smokers reported in the 2008 
NATSISS. 
Within the TATS project sample, we 
assessed the association between 
variables using logistic regression, 
with confidence intervals adjusted 
2  Use of nicotine replacement therapy (NRT) or stop-smoking medicines (SSMs) by dependent Aboriginal and Torres Strait 
Islander smokers,* by sociodemographic factors (n = 1124)
Ever used NRT or SSMs Used NRT or SSMs in the past year
Sociodemographic factor % (frequency)† Odds ratio (95% CI)‡ P§ % (frequency)† Odds ratio (95% CI)‡ P§
All dependent smokers 39% (432) 24% (270)
Age (years) 0.002 0.08
18–24 28% (59) 1.0 18% (39) 1.0
25–34 35% (102) 1.43 (0.98–2.08) 23% (67) 1.35 (0.91–2.02)
35–44 40% (112) 1.78 (1.12–2.83) 24% (65) 1.37 (0.85–2.23)
45–54 44% (86) 2.07 (1.29–3.33) 29% (55) 1.78 (1.12–2.83)
 55 53% (73) 3.00 (1.79–5.01) 32% (44) 2.13 (1.25–3.64)
Sex 0.18 0.11
Female 41% (233) 1.0 27% (150) 1.0
Male 36% (199) 0.80 (0.58–1.11) 22% (120) 0.77 (0.55–1.07)
Indigenous status 0.14 0.76
Aboriginal 40% (398) 1.0 25% (245) 1.0
Torres Strait Islander or both 31% (34) 0.70 (0.44–1.12) 23% (25) 0.93 (0.56–1.52)
Labour force status < 0.001 0.02
Employed 45% (166) 1.0 29% (105) 1.0
Unemployed 30% (113) 0.51 (0.38–0.70) 20% (76) 0.62 (0.45–0.86)
Not in labour force 41% (151) 0.85 (0.64–1.14) 24% (88) 0.80 (0.56–1.14)
Highest education attained 0.001 0.03
Less than Year 12 35% (206) 1.0 21% (127) 1.0
Finished Year 12 38% (109) 1.18 (0.88–1.58) 26% (73) 1.28 (0.92–1.78)
Post-school qualification 50% (115) 1.90 (1.36–2.67) 30% (68) 1.58 (1.12–2.23)
Treated unfairly because Indigenous in 
past year
0.01 0.02
No 43% (207) 1.0 28% (135) 1.0
Yes 35% (214) 0.71 (0.54–0.92) 21% (129) 0.68 (0.50–0.93)
Remoteness 0.002 0.03
Major cities 43% (127) 1.0 29% (85) 1.0
Inner and outer regional 41% (239) 0.94 (0.60–1.47) 25% (141) 0.80 (0.53–1.20)
Remote and very remote 27% (66) 0.50 (0.31–0.80) 18% (44) 0.54 (0.34–0.86)
Area-level disadvantage 0.03 0.02
1st quintile (most disadvantaged) 33% (141) 1.0 19% (81) 1.0
2nd and 3rd quintiles 41% (189) 1.40 (1.01–1.94) 27% (122) 1.54 (1.09–2.17)
4th and 5th quintiles 45% (102) 1.64 (1.07–2.51) 30% (67) 1.78 (1.10–2.87)
Local health service has dedicated 
tobacco control resources
0.006 0.003
No 31% (97) 1.0 18% (57) 1.0
Yes 42% (335) 1.66 (1.16–2.37)  27% (213) 1.70 (1.20–2.39)  
* Daily smokers with Heaviness of Smoking Index scores  2. † Percentages and frequencies exclude those answering “don’t know” or refusing to answer. ‡ Odds ratios calculated 
using simple logistic regression adjusted for the sampling design. § P values for the entire variable, using adjusted Wald tests.  
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for the sampling design, using the 
35 sites as clusters and the age–sex 
quotas as strata in Stata 13 (StataCorp) 
survey [SVY] commands).16 P values 
were calculated for each variable 
using adjusted Wald tests. However, 
we used χ 2 tests to assess the associa-
tion of variables with beliefs about 
whether NRT and SSMs help in quit-
ting, and the association of past use 
with reasons for not intending to use 
them in the future. Median dura-
tions of NRT use are reported with 
interquartile ranges (IQRs) and were 
compared using the non-parametric 
equality of medians test.
Reported percentages and frequen-
cies exclude those refusing to answer 
or answering “don’t know”, except 
for questions on future interest in 
NRT or SSM use and whether they 
help in quitting, which include those 
answering “don’t know”. Less than 
2% of smokers and recent ex-smokers 
answered “don’t know” or refused 
to answer each of the questions ana-
lysed here.
Results
Compared with other daily 
Australian smokers in the ITC Project, 
lower proportions of Aboriginal and 
Torres Strait Islander daily smokers 
reported ever using any NRT or 
SSMs (37% [515/1379] v 58.5% [95% 
CI, 42.8%–72.6%]) and having used 
them in the past year (23% [318/1369] 
v 42.1% [95% CI, 29.4%–56.0%]).
Among all Aboriginal and Torres 
Strait Islander smokers and recent ex-
smokers in the TATS project sample, 
29% (501/1700) had ever used NRT 
and 11% (193/1700) had used SSMs. 
Nicotine patches were the most com-
monly used, by 24% (415/1699), fol-
lowed by varenicline (11%; 183/1699), 
nicotine gum (10%; 174/1699), loz-
enges (3%; 50/1699), and inhalers (3%; 
50/1699). Only 1% (17/1699) had used 
bupropion.
Of the Aboriginal and Torres Strait 
Islander smokers and recent ex-smok-
ers who had used NRT within the 
past year, most had last got it from 
an Aboriginal medical service (46%; 
99/216), pharmacy (31%; 66/216) or 
another local health service (15%; 
32/216), with only 3% (6/216) getting 
it from an ordinary store. Three-
quarters (74%; 161/217) got their NRT 
at no cost, including almost all who 
got it from an Aboriginal medical 
service (93%; 92/99) or another local 
health service (91%; 29/32).
Of the Aboriginal and Torres Strait 
Islander smokers and recent ex-smok-
ers who had used NRT within the 
past year but were currently not using 
it, only 9% (16/174) had used it for the 
recommended period of more than 2 
months;7-9 49% (85/174) used it for a 
week or less and 79% (138/174) for a 
month or less. The median duration 
of NRT use was 14 days (IQR, 3–30 
days), with no significant differences 
by HSI score or whether it was free.
Aboriginal and Torres Strait Islander 
daily smokers who were more 
dependent, according to the HSI and 
RACGP criteria, were more likely to 
have ever used NRT or SSMs than 
those who were less dependent 
(Box 1). Fewer non-daily smokers 
than daily smokers or recent ex-
smokers had ever used them. These 
associations were similar but less 
marked for use in the past year.
Among Aboriginal and Torres Strait 
Islander smokers who were at least 
moderately dependant (HSI score 
 2), the group for whom NRT and 
SSMs are recommended, those who 
were socioeconomically advantaged 
were more likely than the disadvan-
taged to have ever used NRT or SSMs 
and to have used them in the past 
3  Aboriginal and Torres Strait Islander smokers and recent ex-smokers’ beliefs about whether nicotine replacement therapy 
(NRT) and stop-smoking medicines (SSMs) help smokers to quit*
Do you think NRT and SSMs help smokers to quit?
Smoker characteristics Very much Somewhat Not at all
Don’t know or haven’t 
heard of them P†
Smokers and recent ex-smokers (n = 1721) 20% (337) 51% (867) 16% (274) 14% (234)‡
Ever used NRT or SSMs < 0.001
Yes 31% (179) 55% (324) 9% (50) 5% (32)
No 14% (158) 48% (541) 20% (223) 18% (196)
Used NRT or SSMs in the past year < 0.001
Yes 35% (132) 53% (197) 7% (27) 5% (17)
No 15% (203) 50% (659) 19% (245) 16% (211)
Smoking status 0.2
Daily smokers 19% (268) 51% (700) 16% (218) 14% (197)
Non-daily smokers 18% (45) 53% (132) 18% (44) 12% (30)
Recent ex-smokers§ 31% (24) 45% (35) 15% (12) 9% (7)  
Daily smokers only (n = 1383)      
Heaviness of Smoking Index score 0.007
Low (0–1) 17% (39) 49% (115) 14% (33) 20% (46)
Moderate (2–3) 20% (161) 53% (416) 14% (112) 13% (103)
Heavy (4–6) 19% (61) 46% (149) 22% (70) 14% (45)
* Percentages and frequencies exclude those answering “don’t know” or refusing to answer, except for whether NRT and SSMs help, which do include those answering “don’t know”. 
† P values were calculated using the χ  2 test adjusted for sampling design. ‡ Comprises 19 smokers and recent ex-smokers who had not heard of NRT and SSMs, and 215 who did not 
know if they helped smokers to quit. § Those who had quit  12 months before.  
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year (Box 2). Use decreased with 
increasing remoteness and area-level 
disadvantage, increased with edu-
cation, and was lower among those 
who reported being treated unfairly 
in the past year because they were 
Indigenous. Use also increased with 
age and was higher among smok-
ers whose local health service had 
dedicated tobacco control resources. 
Those who were socioeconomically 
disadvantaged were even less likely 
to use SSMs than NRT (Appendix 2).
Most Aboriginal and Torres Strait 
Islander daily smokers said NRT 
and SSMs help smokers to quit: 
70% said they help “very much” or 
“somewhat”, 16% said “not at all” and 
14% did not know (Box 3). Similarly, 
the Australian ITC Project reported 
that 74.2% (95% CI, 68.9%–78.9%) of 
Australian daily smokers agreed 
that NRT and SSMs would make it 
easier to quit, 11.0% (95% CI, 8.7%–
13.8%) disagreed, and 14.8% (95% 
CI, 10.8%–20.0%) neither agreed nor 
disagreed or did not know.
Having used NRT or SSMs was 
strongly associated with Aboriginal 
and Torres Strait Islander smokers 
believing that they help in quitting. 
Heavy smokers were more likely to 
believe that they would not help at 
all (Box 3).
Dependent Aboriginal and Torres 
Strait Islander smokers who believed 
NRT and SSMs would help in quit-
ting and those who had used them 
(ever or in the past year) were more 
likely to be interested in using them 
in the future (Box 4). Frequency of 
strong urges to smoke and strong 
cravings on the most recent quit 
attempt were not associated with 
interest in future use of NRT and 
SSMs (data not shown). 
The main reasons given by dependent 
smokers who were not interested in 
using NRT and SSMs in future were 
that they were not ready to quit (NRT, 
36% [162/445]; SSMs, 29% [131/449]), 
because of side effects (19% [85/445]; 
25% [114/449]), they did not think 
they would work (18% [81/445]; 16% 
[73/449]) and they preferred not to 
use them (16% [73/445]; 18% [82/449]). 
Cost was rarely mentioned as a rea-
son (3% [15/445]; 2% [10/449]). There 
were significant differences between 
the reasons given by those who had 
and had not used NRT or SSMs in 
the past year (P < 0.001). Those who 
had used NRT were more likely than 
those who had not to say they would 
not use it in the future because of side 
effects (45% [26/58] v 15% [59/386]) 
and were less likely to report not 
being ready to quit (12% [7/58] v 40% 
[155/386]).
Discussion
We found lower use of NRT and 
SSMs among daily smokers in a 
4 Interest in using nicotine replacement therapy (NRT) or stop-smoking medicines (SSMs) to help quit smoking in the future 
among dependent Aboriginal and Torres Strait Islander smokers* (n = 1124)
Interested in using NRT in the future Interested in using SSMs in the future
% (frequency)†
Odds ratio 
(95% CI)‡ P§
% (frequency)†
Odds ratio 
(95% CI)‡ P§Variable Yes No Don’t know Yes No Don’t know
All dependent smokers 54% (608) 41% (462) 4% (47) 51% (575) 42% (470) 7% (73)
Think NRT and SSMs help 
smokers to quit
< 0.001 < 0.001
Not at all 24% (43) 73% (132) 4% (7) 1.0 23% (42) 74% (134) 3% (6) 1.0
Somewhat 59% (335) 37% (211) 3% (19) 4.87 
(3.19–7.45)
58% (325) 37% (209) 5% (31) 4.96 
(3.18–7.73)
Very much 80% (177) 18% (40) 2% (4) 13.58 
(8.29–22.26)
74% (164) 23% (51) 3% (7) 10.26 
(6.3–16.7)
Don’t know or haven’t 
heard of them
36% (53) 53% (78) 11% (17) 30% (44) 51% (75) 20% (29)
Ever used NRT or SSMs < 0.001 < 0.001
No 48% (352) 48% (354) 5% (34) 1.0 48% (461) 46% (438) 6% (62) 1.0
Yes 69% (255) 29% (106) 2% (8) 2.42 
(1.82–3.22)
75% (112) 21% (31) 4% (6) 3.43 
(2.22–5.31)
Used NRT or SSMs in the 
past year
< 0.001 < 0.001
No 49% (427) 46% (401) 5% (41) 1.0 49% (499) 45% (454) 6% (65) 1.0
Yes 74% (176) 25% (60) 1% (2) 2.75 
(1.95–3.90)
78% (72) 17% (16) 4% (4) 4.09 
(2.21–7.57)
Heaviness of Smoking Index 
score
0.05 < 0.001
Moderate (2–3) 56% (446) 39% (311) 4% (34) 1.0 53% (418) 41% (323) 6% (51) 1.0
Heavy (4–6) 50% (162) 46% (151) 4% (13) 0.75 
(0.56–0.99)
48% (157) 45% (147) 7% (22) 0.83 
(0.62–1.09)
* Daily smokers with Heaviness of Smoking Index scores  2. † Percentages and frequencies exclude those answering “don’t know” or refusing to answer, except for questions on 
future interest in NRT or SSM use and whether they help in quitting, which include those answering “don’t know”. ‡ Odds ratios calculated using simple logistic regression adjusted for 
the sampling design. § P values for the entire variable, using adjusted Wald tests.  
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large nationally representative 
Aboriginal and Torres Strait Islander 
sample than among those in the gen-
eral Australian population. This is 
consistent with research in various 
countries that has found that smokers 
from more disadvantaged groups are 
less likely to use these medicines.17,18 
We also found a social gradient of 
reducing use with increasing disad-
vantage (including perceived experi-
ences of racism) within the Aboriginal 
and Torres Strait Islander community. 
Consistent with previous research, 
we found this gradient was steeper 
for the use of varenicline (bupropion 
accounted for very little of the SSM 
use) than for NRT.18,19 
In recent years, many ACCHSs and 
their government funders have 
increased their focus on, and directed 
significant resources towards, tobacco 
control and cessation support. Our 
finding of greater use of SSMs by 
smokers whose local ACCHS had 
dedicated tobacco control resources 
provides some evidence for the 
effect of these policy decisions. We 
explore other non-pharmacological 
cessation support elsewhere in this 
supplement.20
Early research into Aboriginal and 
Torres Strait Islander smokers’ use 
of SSMs focused on the disincentive 
of the cost of NRT, and interventions 
to subsidise or provide free NRT.21-24 
Covering the costs of treatment 
has been demonstrated to increase 
the use of NRT and bupropion in 
other contexts.25,26 Following policy 
changes, we found that nearly three-
quarters of participants had got their 
most recent NRT at no cost, remov-
ing this financial impediment to its 
use. Unlike earlier research, cost was 
rarely given as a reason in our survey 
for not intending to use NRT or SSMs 
in the future.21,23 While some smokers 
are still paying a proportion of the 
cost, it is reassuring that policies to 
provide access to free NRT seem to be 
effectively reaching many Aboriginal 
and Torres Strait Islander smokers.
It is encouraging that a similar pro-
portion of Aboriginal and Torres 
Strait Islander daily smokers as those 
in the broader Australian population 
think these medicines assist cessa-
tion. Further, Aboriginal and Torres 
Strait Islander smokers who were 
more dependent were more likely 
than the less dependent to have used 
them, in accordance with current 
clinical guidelines. However, there 
is still opportunity to improve their 
use. The clinical guidelines can be 
better promoted during the training 
and ongoing education of clinicians 
and tobacco control workers, to ena-
ble more frequent discussion about 
them with smokers. There remains 
a large proportion of Aboriginal and 
Torres Strait Islander smokers who 
have never used these medicines, 
are less likely to think they help and 
less likely to use them in the future, 
who could be informed about their 
effectiveness in assisting quitting.27
The frequent use of NRT for much 
less than the recommended 8 weeks 
is similar to earlier reports in this 
population; likewise, the median 
duration was similar to those found 
in other research in Australia and 
elsewhere, particularly the shorter 
durations reported when NRT is 
available over the counter rather 
than by prescription.22,28-31 Research 
into the common reasons for stop-
ping NRT and SSMs (resuming 
smoking, side effects and the belief 
that it has already worked) suggests 
that these are generally legitimate 
and may not be cause for great con-
cern. For example, data from other 
ITC Project surveys show that 66% of 
those who stopped early because they 
believed that they no longer needed 
the medication were still abstinent 
at 6 months.30
There has been a significant increase 
in the use of SSMs in Australia in 
recent years, especially associated 
with the release of varenicline in 
2008.32 The release of new varieties 
of NRT and other SSMs has also 
been shown to be associated with 
this increase in the total use of SSMs, 
often with very little compensatory 
decline in the use of older medi-
cines.19,26,32 We found that a variety of 
types of NRT were used (most com-
monly patches), as well as varenicline 
and a small amount of bupropion. 
The range of NRT formulations and 
other medicines is likely to increase 
in the future.3 The potential impact 
of e-cigarettes as an aid to cessation 
remains unclear and contested.33,34
Strengths and limitations
The main strength of our study is its 
large national sample of Aboriginal 
and Torres Strait Islander smokers, 
providing the first detailed national 
information about the use of NRT and 
SSMs in this population. However, it 
is a non-random, albeit broadly rep-
resentative, sample, and caution is 
needed in interpreting the compari-
sons with the Australian ITC Project 
sample and in generalising the results 
to the whole Aboriginal and Torres 
Strait Islander population. The use 
of NRT or SSMs in our sample of 
Aboriginal and Torres Strait Islander 
people in communities served by 
ACCHSs may be different to that in 
communities without access to an 
ACCHS, who use private general 
practices. Our self-reported data are 
probably limited by incomplete recall 
of past use of NRT and SSMs and quit 
attempts. The effect of these biases 
will be to weaken reported associa-
tions, leading to greater confidence 
in the significant associations but re-
quiring caution in the implications of 
findings of no association.
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